AGM/EGMApr 27, 2026, 04:13 PM
MCRB Sets June 9, 2026 Annual Meeting; Key Proposals Outlined
AI Summary
Seres Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, at 8:00 a.m. Eastern Time. The meeting will be held virtually, and stockholders of record as of April 13, 2026, are eligible to vote. Key proposals include the election of three Class II Directors, ratification of the independent auditor, an advisory vote on executive compensation, and approval of an amendment to the 2025 Incentive Award Plan to increase available shares.
Key Highlights
- Annual Meeting of Stockholders to be held virtually on June 9, 2026, at 8:00 a.m. Eastern Time.
- Stockholders of record as of April 13, 2026, are entitled to vote.
- Proposals include election of three Class II Directors: Stephen A. Berenson, Claire M. Fraser, Ph.D., and Richard N. Kender.
- Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026.
- Advisory (non-binding) vote on named executive officers' compensation.
- Approval of an amendment and restatement of the 2025 Incentive Award Plan to increase shares available.
- Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies for Proposal 4.
Price Impact
More from MCRB